For the quarter ending 2025-09-30, HRGN had $533K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,700 | -3,482 |
| Share-based compensation expense | 495 | 1,022 |
| Depreciation | 1 | 3 |
| Amortization of operating lease right-of-use assets | 24 | 48 |
| Accounts receivable | -2 | -226 |
| Inventory | -5 | -53 |
| Prepaid research and development | 0 | -37 |
| Prepaid expenses and other current assets | -16 | -101 |
| Deferred financing costs | 0 | 0 |
| Long-term prepaid contracts | -76 | -137 |
| Accounts payable | -39 | -100 |
| Operating lease liability | -25 | -45 |
| Accrued and other current liabilities | -236 | 342 |
| Deferred revenue | -21 | 149 |
| Insurance premium financing payable-Insurance Premium Financing Payable | -63 | -190 |
| Net cash used in operating activities | -1,465 | -1,699 |
| Proceeds from convertible debt related party-Related Party | 0 | 0 |
| Proceeds from issuance of common stock | 2,000 | 0 |
| Proceeds from exercise of warrants | 0 | - |
| Payments on convertible debt - related party-Related Party | 0 | - |
| Net cash provided by financing activities | 2,000 | 0 |
| Effect of exchange rate changes on cash | -2 | -1 |
| Net decrease in cash and cash equivalents | 533 | -1,700 |
| Cash and cash equivalents at beginning of period | 2,486 | - |
| Cash and cash equivalents at end of period | 1,319 | - |
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
Harvard Apparatus Regenerative Technology, Inc. (HRGN)